Leg Muscle May Flag Insulin Resistance in Older Adults

Preserving leg muscle may help identify older adults headed toward insulin resistance before diabetes develops. That is useful, but it is not a license to claim that adding muscle prevents heart attacks or diabetes. The best direct evidence tracks a metabolic marker, not clinical events, and muscle quality, body fat, activity, and baseline insulin resistance all complicate the picture.

The practical point is still worth taking seriously. Skeletal muscle handles a large share of the body's glucose disposal, so declining muscle can travel with worsening metabolic health. For adults over 65, lower-limb and appendicular muscle mass may belong on the list of risk signals alongside waist circumference, glucose measures, activity, and strength—not as a stand-alone diagnosis.

What the prospective study actually found

The anchor evidence comes from Seko et al.'s 2023 prospective cohort study of adults aged 65 and older without diabetes. After accounting for baseline metabolic status and key covariates, people with greater lower-limb muscle mass had a lower subsequent risk of developing insulin resistance, with a hazard ratio of 0.88 (95% CI, 0.79 to 0.98). Greater appendicular muscle mass—the muscle in the arms and legs—showed a similar association: hazard ratio 0.89 (95% CI, 0.81 to 0.99).

Both confidence intervals exclude 1.0, so these associations were statistically significant by conventional criteria. The result does not tell us the absolute difference in risk between people with more and less muscle, nor does it establish how much additional muscle someone would need to gain to change that risk. It does show that preserved limb muscle tracked with a lower chance of later insulin resistance in this specific older, nondiabetic population.

The study also puts a brake on the familiar advice to simply get stronger. Its abstract highlighted other sarcopenia-related measures, but it did not report the same predictive pattern for the functional measures listed there. In this cohort, the metabolic signal belonged to muscle mass rather than strength or walking performance alone. Strength still matters greatly for independence and fall prevention; it just did not carry the same reported association with future insulin resistance here.

Why muscle could matter metabolically

The biological case is plausible. Muscle tissue participates directly in glucose handling, and metabolically unhealthy muscle may also handle fat differently. In a 2023 human skeletal-muscle study by Poppelreuther et al., obesity and insulin resistance were associated with reduced expression of acyl-CoA synthetases in muscle. These enzymes help activate fatty acids for cellular use.

This is mechanistic evidence, not proof that altered enzyme expression causes insulin resistance or that a training program fixes it. Still, it supports the idea that muscle is part of the insulin-resistance phenotype rather than merely a passive casualty of poor health.

Quantity also misses part of the story. Kim et al.'s 2025 study of muscle quality found that muscle quality contributed to strength and physical performance beyond muscle mass or diabetes status. Myosteatosis—fat accumulation within muscle—can leave a person with more lean tissue on paper than their function and metabolic profile would suggest. A body-composition result is therefore a clue, not a complete metabolic report card.

Genetic evidence supports a pathway, not a prescription

A 2023 Mendelian randomization study by Ye et al. examined four sarcopenia-related traits across six cardiometabolic outcomes and Alzheimer's disease. The investigators also tested insulin resistance as a mediator. That design uses genetic variants associated with traits as tools for causal inference, making it less vulnerable than ordinary observational studies to some forms of confounding and reverse causation.

The study supports insulin resistance as one plausible route through which poorer muscle-related traits may connect to later cardiometabolic disease. It does not show that a 70-year-old who adds leg muscle through resistance training will reduce their risk of myocardial infarction, stroke, coronary disease, or diabetes by the same mechanism. Genes are assigned before birth; training, diet, fat loss, illness, medication, and adherence arrive later and make the real world considerably less tidy.

Why a mass-only strategy can mislead

Muscle status and insulin resistance appear to interact rather than operate on separate tracks. Moon et al.'s 2025 mortality analysis examined appendicular skeletal muscle mass index and insulin resistance together in multinational cohorts. Its framing matters: downstream mortality risk belongs to the combination of muscle status and metabolic dysfunction, not to muscle mass in isolation.

Training response also varies. In a 2022 study of postmenopausal women, Orsatti et al. linked heterogeneity in resistance-training strength responses with training frequency and insulin resistance. The finding does not establish that insulin resistance caused weaker training responses, but it makes a one-size-fits-all promise hard to defend. Two people can follow similar programs and get different changes in strength, body composition, and metabolic markers.

Intervention evidence remains preliminary. Wang et al.'s 2025 open-label, single-arm trial tested nutritional and exercise strategies intended to prevent or reverse sarcopenia in aging. Without randomization or a control group, the study cannot isolate lower-limb muscle gain as the active ingredient, separate it from dietary changes or fat loss, or show that hypertrophy produced a metabolic benefit.

What to do with this information

For older adults, preserving and building leg and appendicular muscle is a sensible part of a broader health plan. Resistance training can support strength, mobility, and muscle retention, while adequate nutrition, aerobic activity, sleep, weight management, and routine screening address the rest of the metabolic picture.

Use muscle measures as a prompt for a fuller assessment, especially when lean mass is falling alongside reduced activity, increasing abdominal fat, rising glucose, or declining function. Do not treat a low muscle measurement as proof of insulin resistance, and do not treat a higher measurement as immunity.

Verdict: Lower-limb and appendicular muscle mass are credible metabolic-risk markers in older adults. Current evidence does not prove that muscle gain alone prevents diabetes or cardiovascular events.

The distinction matters because it keeps the advice useful. The cohort evidence supports watching muscle loss; the genetic and tissue-level evidence make the link to insulin resistance biologically credible. What the field still needs are randomized trials showing that targeted gains in lower-limb or appendicular muscle improve insulin sensitivity independently of fat loss and then reduce clinical cardiometabolic events.